Orforglipron

1. **Administration Method:** Once-daily oral administration of a GLP-1 medication. This completely eliminates patients' fear of injections and the associated inconvenience.

2. **R&D by a Top-Tier Pharmaceutical Company:** Developed by Eli Lilly—a global leader in the diabetes sector—the product benefits from powerful brand endorsement and world-class clinical development resources, ensuring an exceptionally high probability of success.

3. **Clinical Data:** Its efficacy in both blood glucose reduction and weight loss is non-inferior—and in some cases, even superior—to current mainstream injectable GLP-1 medications (such as Semaglutide).

4. **Golden Era of Demand:** With the original patent nearing expiration, a prime window for the development of generic drugs and biosimilars has opened; this marks a pivotal moment for an explosive surge in demand for raw materials and intermediates.

5. **Core Supply Chain Advantage:** Our company is the largest manufacturer of Ogrelotin intermediates in the Chinese market. We possess comprehensive, large-scale supply capabilities spanning the entire chain—from key fragments to advanced intermediates—thereby ensuring the secure, compliant, and efficient advancement of our clients' projects.